180 Life Sciences (NASDAQ:ATNF) Corp COO Quan Vu talks to Proactive about recent developments regarding the group's lead indication Dupuytren’s disease, a condition that gradually causes connective tissue under the skin of a hand to thicken and become scar-like. Vu says its Phase 2b trial using a repurposed anti-tumor necrosis factor named adalimumab met its primary and secondary endpoints, with no serious adverse events. Vu details anticipated next steps.
180 Life Sciences Corp describes recent milestones with lead indication in Dupuytren’s disease
